Trials / Active Not Recruiting
Active Not RecruitingNCT03614689
Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 104 (actual)
- Sponsor
- Geneplus-Beijing Co. Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To analyze the proportion of hereditary tumors in ovarian cancer patients in China, as well as the spectrum of variations; the ctDNA characteristics in patients with ovarian cancer; the correlation between the clonal status of mutations and therapy response; whether ctDNA detection can be used to predict the risk of ovarian cancer recurrence; and the characteristics of immune repertoire before and after treatment in patients with ovarian cancer.
Detailed description
100 OC cases with available matched tumor DNA and plasma will be collected. All patients will be treated according to clinical guidelines, and receive circulating tumor DNA (ctDNA) liquid biopsy at the time of diagnosis, at mid treatment, at the end of treatment and during follow-up. The study will be ended when the patients have progressive disease (PD) or reach the longest follow-up time (2 years).
Conditions
Timeline
- Start date
- 2017-11-25
- Primary completion
- 2020-11-30
- Completion
- 2024-12-01
- First posted
- 2018-08-03
- Last updated
- 2024-07-18
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03614689. Inclusion in this directory is not an endorsement.